ClinicalTrials.gg
CompletedNCT06115304Updated Oct 23, 2026

Postprandial Profiles of Metabolites and Appetite-regulating Hormones in Plasma and Cerebrospinal Fluid

An Early Phase 1 interventional study of Large liquid meal, spinal catheter and venous line in Obesity and Diabetes Mellitus, Type 2, sponsored by Mikkel Bring Christensen. Completed at 1 site in Denmark. Open to male participants aged 50 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Mikkel Bring Christensen · Early Phase 1, Interventional, and Basic science

How we know

Updated Oct 23, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
50 Years to 70 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 351 studies in Obesity with a site in Denmark — 58 open to participants now, 85 under way, 23 of them phase 3. Obesity · Denmark.

Enrollment
208th of 283
24 · median 72
Started
2023
with 17 others
Phase 1
14 of 351
4 open now
Registered
272nd of 351
by date

Among the 351 studies in Obesity with a site in Denmark, this one is the 208th largest by enrollment of the 283 interventional ones that give a count, is one of 18 that started in 2023, is one of 14 in phase 1, and was the 272nd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

58 of the 351 studies in Obesity with a site in Denmark are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 50 Years to 70 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 351 studies in Obesity with a site in Denmark, or all of them as a file.
02

Study summary

Overweight and obesity are rising in prevalence and becoming a growing threat to public health. Obesity is associated with an increased all-cause mortality, impaired quality of life, and numerous of disorders. Therapeutic strategies against obesity - which include an abundance of dietary and physical training programmes and pharmaceutical drugs to increase energy expenditure or limit appetite or gastro-intestinal fat absorption - have shown limited success on long term weight loss. Thus, overweight and associated conditions is becoming the new normal and there is a need for better understanding gut-to-brain signalling, hormonal and metabolic disturbances in overweight individuals.

The purpose of this health science research project is to describe the coinciding plasma and cerebrospinal fluid (CSF) profiles of selected biomarkers after co-ingestion of a meal and model pharmaceuticals in patients with overweight and/or type 2 diabetes compared to healthy control individuals.

03

Conditions studied

  • Obesity
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 10 male patients with obesity ( >30) and type 2 diabetes
  • 10 male volunteers with normal weight (BMI 20-24) matched by age
  • 10 male volunteers with obesity (BMI >30) matched by age

Exclusion criteria

Exclusion Criteria:

  1. Unwillingness to participate or wish to withdraw from ongoing protocol
  2. Hepatic disease or hemorrhagic diatheses (including abnormal (INR), , blood levels of , alanine-aminotransferase (ALAT))
  3. Anticoagulant treatment (e.g. treatment with warfarin, apixaban or another oral anticoagulant)
  4. Anaemia (p- below normal range)
  5. Nephropathy (se-creatinine >130 μM and/or albuminuria)
  6. Suspected difficult access to the spinal canal (e.g. pronounced scoliosis, spinal stenosis, osteoporotic coincidence in the lower back, spina bifida, meningocele after surgical intervention)
  7. Lumbar skin infection (e.g. herpes zoster, pustules or ulcers)
  8. Medical history with headaches - both in connection with dura puncture and frequent headaches of other types
  9. Central nervous system disease (including dementia, previous stroke, multiple sclerosis, epilepsy, etc.)
  10. Clinical suspicion of increased intracranial pressure (headaches, visual disturbances etc.)
  11. Patients with type 2 diabetes: Treatment with DPP-4 inhibitor or GLP-1 receptor agonist. Late diabetic complications including proliferative diabetic retinopathy (anamnestic), arteriosclerotic cardiovascular disease (heart failure or previous ischemic event/myocardial infarction)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Other
    Intervention arm

    Other: Large liquid meal, spinal catheter and venous line

Interventions

  • OtherLarge liquid meal, spinal catheter and venous line

    Large liquid meal (e.g. Nutricia® Energy 500 ml (750 kcal) admixed paracetamol 1000 mg (for estimation of gastric emptying) and Caffeine (to prevent postspinal headache). Spinal catheter for 4 hours, with samples taken at one hour interval. 2 venous lines, one for saline and one for venous sampling every half hour

06

What researchers measure

Primary outcomes

  1. Appetite regulating hormones measured by specific immunoassays

    Time frame: After 1 hour

  2. Appetite regulating hormones measured by specific immunoassays

    Time frame: After 2 hour

  3. Appetite regulating hormones measured by specific immunoassays

    Time frame: After 3 hours

  4. Appetite regulating hormones measured by specific immunoassays

    Time frame: After 4 hours

Other outcomes

  1. Metabolomics measured in blood and cerebrospinalfluid using mass spectrometry

    Time frame: After 1 hour

  2. Metabolomics measured in blood and cerebrospinalfluid using mass spectrometry

    Time frame: After 2 hours

  3. Metabolomics measured in blood and cerebrospinalfluid using mass spectrometry

    Time frame: After 3 hours

  4. Metabolomics measured in blood and cerebrospinalfluid using mass spectrometry

    Time frame: After 4 hours

  5. Proteomics measured in blood and cerebrospinalfluid using mass spectrometry

    Time frame: After 1 hour

  6. Proteomics measured in blood and cerebrospinalfluid using mass spectrometry

    Time frame: After 2 hours

  7. Proteomics measured in blood and cerebrospinalfluid using mass spectrometry

    Time frame: After 3 hours

  8. Proteomics measured in blood and cerebrospinalfluid using mass spectrometry

    Time frame: After 4 hours

  9. Peptidomics measured in blood and cerebrospinalfluid using mass spectrometry

    Time frame: After 1 hour

  10. Peptidomics measured in blood and cerebrospinalfluid using mass spectrometry

    Time frame: After 2 hour

  11. Peptidomics measured in blood and cerebrospinalfluid using mass spectrometry

    Time frame: After 3 hours

  12. Peptidomics measured in blood and cerebrospinalfluid using mass spectrometry

    Time frame: After 4 hours

  13. Paracetamol concentrations measured in blood and cerebrospinalfluid

    Time frame: After 1 hour

  14. Paracetamol concentrations measured in blood and cerebrospinalfluid

    Time frame: After 2 hours

  15. Paracetamol concentrations measured in blood and cerebrospinalfluid

    Time frame: After 3 hours

  16. Paracetamol concentrations measured in blood and cerebrospinalfluid

    Time frame: After 4 hours

  17. Caffeine concentrations measured in blood and cerebrospinalfluid

    Time frame: After 1 hour

  18. Caffeine concentrations measured in blood and cerebrospinalfluid

    Time frame: After 2 hours

  19. Caffeine concentrations measured in blood and cerebrospinalfluid

    Time frame: After 3 hours

  20. Caffeine concentrations measured in blood and cerebrospinalfluid

    Time frame: After 4 hours

07

Study locations

1 site
  • Deparrtment of clinical pharmacology
    Copenhagen, 2400, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Aug 2024, 10 months.

Of 105 non-industry phase 1 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 57. This study's 10 months is below that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Oct 2024 → Aug 2024 and completion Oct 2024 → Aug 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2023
First posted
Nov 3, 2023
StartActual
Oct 5, 2023
Primary completionActual
Aug 26, 2024was Oct 2024
CompletionActual
Aug 26, 2024was Oct 2024
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 23, 2026
Primary completion
Oct 5, 2024→Aug 26, 2024 (actual)
Oct 23, 2026
Study completion
Oct 10, 2024→Aug 26, 2024 (actual)
Oct 23, 2026
Enrollment
30 (estimated)→24 (actual)
Oct 23, 2026
Secondary outcomes
1 edited, 8 added
What changed in the outcomes
  • Editedother outcomePeptidomicsmeasuredPeptidomics measured in blood and cerebrospinalfluid using mass spectrometryTime frame: After 4 hours
  • Addedother outcomeParacetamol concentrations measured in blood and cerebrospinalfluidTime frame: After 1 hour
  • Addedother outcomeParacetamol concentrations measured in blood and cerebrospinalfluidTime frame: After 2 hours
  • Addedother outcomeParacetamol concentrations measured in blood and cerebrospinalfluidTime frame: After 3 hours
  • Addedother outcomeParacetamol concentrations measured in blood and cerebrospinalfluidTime frame: After 4 hours
  • Addedother outcomeCaffeine concentrations measured in blood and cerebrospinalfluidTime frame: After 1 hour
  • Addedother outcomeCaffeine concentrations measured in blood and cerebrospinalfluidTime frame: After 2 hours
  • Addedother outcomeCaffeine concentrations measured in blood and cerebrospinalfluidTime frame: After 3 hours
  • Addedother outcomeCaffeine concentrations measured in blood and cerebrospinalfluidTime frame: After 4 hours
Oct 23, 2026
Design
Not applicable→Early Phase 1
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Recruiting→Completed
    Primary completion Oct 5, 2024→Aug 26, 2024 (now actual)
    Study completion Oct 10, 2024→Aug 26, 2024 (now actual)
    Enrollment 30 (estimated)→24 (actual)
    Secondary outcomes 1 edited, 8 added
    What changed in the outcomes
    • Editedother outcomePeptidomicsmeasuredPeptidomics measured in blood and cerebrospinalfluid using mass spectrometryTime frame: After 4 hours
    • Addedother outcomeParacetamol concentrations measured in blood and cerebrospinalfluidTime frame: After 1 hour
    • Addedother outcomeParacetamol concentrations measured in blood and cerebrospinalfluidTime frame: After 2 hours
    • Addedother outcomeParacetamol concentrations measured in blood and cerebrospinalfluidTime frame: After 3 hours
    • Addedother outcomeParacetamol concentrations measured in blood and cerebrospinalfluidTime frame: After 4 hours
    • Addedother outcomeCaffeine concentrations measured in blood and cerebrospinalfluidTime frame: After 1 hour
    • Addedother outcomeCaffeine concentrations measured in blood and cerebrospinalfluidTime frame: After 2 hours
    • Addedother outcomeCaffeine concentrations measured in blood and cerebrospinalfluidTime frame: After 3 hours
    • Addedother outcomeCaffeine concentrations measured in blood and cerebrospinalfluidTime frame: After 4 hours
    Design Not applicable→Early Phase 1
    + 4 other changes: arm descriptions, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06115304
Lead sponsor
Mikkel Bring Christensen
Responsible party
Mikkel Bring Christensen (Chief consultent at the department of Clinical Pharmacology, Bispebjerg Hospital) — Sponsor-investigator
First posted
Nov 3, 2023
Start date
Oct 5, 2023
Primary completion
Aug 26, 2024
Completion
Aug 26, 2024
Last update
Oct 23, 2026

Study contacts

Mikkel.bring.christensen@regionh.dk B Christensen, MD, PhD
principal investigator · Department of clinical pharmacology, Bispebjerg Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion